

HALOZYME THERAPEUTICS INC

Form 8-K

February 09, 2007

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of The  
Securities Exchange Act of 1934**

**February 5, 2007**

**HALOZYME THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

Nevada

000-49616

88-0488686

(State or other jurisdiction  
of incorporation)

(Commission  
File Number)

(IRS Employer  
Identification No.)

11588 Sorrento Valley Road, Suite 17, San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code: (858) 794-8889

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.***Senior Management Salary Compensation and Annual Bonuses*

On February 5, 2007, the Board of Directors of Halozyme Therapeutics, Inc. (the Company), upon recommendation of the Board's Compensation Committee (the Committee), approved annual cash and equity bonuses for the Company's senior management for 2006. The Board also approved, upon the Committee's recommendation, the annual base salaries of the Company's senior management for 2007. The following table sets forth the 2006 equity and cash bonus amounts for senior management as well as the annual base salary levels for 2007.

|   | 2006 Cash<br>Bonus | 2006 Equity<br>Bonus(1) | 2007 Base<br>Salary |
|---|--------------------|-------------------------|---------------------|
| Jonathan E. Lim (President and Chief Executive Officer)         | \$ 53,550          | 39,603                  | \$ 360,000          |
| Robert Little (Chief Commercial Officer)                        | \$ 21,750(2)       | 10,861(2)               | \$ 307,400          |
| Richard Yocum (Vice President-Clinical Development)             | \$ 36,000          | 17,976                  | \$ 270,000          |
| Gregory I. Frost (Chief Scientific Officer)                     | \$ 31,500          | 15,729                  | \$ 265,000          |
| William Fallon (Vice President-Manufacturing and<br>Operations) | \$ (3)             | (3)                     | \$ 260,000          |
| David A. Ramsay (Chief Financial Officer)                       | \$ 25,650          | 12,943                  | \$ 235,000          |
| Don A. Kennard (Vice President-Regulatory Affairs)              | \$ 30,000          | 14,980                  | \$ 214,000          |

(1) Each 2006 equity bonus is in the form of an incentive stock option to purchase Company common stock. One-third of the total grant amount will become vested on February 5, 2008 and 1/36 of the total amount will become vested for each month of service provided to the Company by the optionee thereafter. The per share exercise price for each option is \$7.51, as this was the closing trading price of the Company's

common stock  
on the American  
Stock Exchange  
on the date of  
grant.

(2) Robert Little  
joined the  
Company  
mid-year and  
his bonus  
amounts are  
prorated based  
on months of  
service provided  
in 2006.

(3) William Fallon  
joined the  
Company in late  
2006 and, by  
virtue of his  
start date, was  
not eligible for a  
2006 bonus.

In determining 2006 bonus amounts for each member of senior management, the Board evaluated a number of criteria related to that individual's performance during 2006 as well as the Company's operational, clinical and financial performance during that same period.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Halozyme Therapeutics, Inc.

February 9, 2007

By: /s/ David A. Ramsay

**David A. Ramsay**

**Secretary and Chief Financial Officer**